Two industry moves targeted long‑standing manufacturing constraints for cell and gene therapies. Sartorius unveiled the Eveo Cell Therapy Platform, an integrated modular system meant to compress vein‑to‑vein timelines and enable decentralized autologous manufacturing by co‑locating production, analytics and QC. Separately, ARPA‑H awarded BioCurie up to $9.3 million to build an AI‑driven digital platform that models and optimizes viral and non‑viral gene‑therapy processes to reduce development trial‑and‑error. Both efforts aim to lower costs, improve reproducibility and expand patient access by tackling throughput, process transfer and analytical bottlenecks across the CGT value chain.